JP2008528621A5 - - Google Patents

Download PDF

Info

Publication number
JP2008528621A5
JP2008528621A5 JP2007553304A JP2007553304A JP2008528621A5 JP 2008528621 A5 JP2008528621 A5 JP 2008528621A5 JP 2007553304 A JP2007553304 A JP 2007553304A JP 2007553304 A JP2007553304 A JP 2007553304A JP 2008528621 A5 JP2008528621 A5 JP 2008528621A5
Authority
JP
Japan
Prior art keywords
composition
administered
des
weeks
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007553304A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008528621A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/003116 external-priority patent/WO2006081510A2/en
Publication of JP2008528621A publication Critical patent/JP2008528621A/ja
Publication of JP2008528621A5 publication Critical patent/JP2008528621A5/ja
Pending legal-status Critical Current

Links

JP2007553304A 2005-01-27 2006-01-27 腎細胞ガンを処置するための方法 Pending JP2008528621A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64749605P 2005-01-27 2005-01-27
PCT/US2006/003116 WO2006081510A2 (en) 2005-01-27 2006-01-27 Methods for treating renal cell carcinoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011266809A Division JP2012046552A (ja) 2005-01-27 2011-12-06 腎細胞ガンを処置するための方法

Publications (2)

Publication Number Publication Date
JP2008528621A JP2008528621A (ja) 2008-07-31
JP2008528621A5 true JP2008528621A5 (cg-RX-API-DMAC10.html) 2009-01-29

Family

ID=36741121

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007553304A Pending JP2008528621A (ja) 2005-01-27 2006-01-27 腎細胞ガンを処置するための方法
JP2011266809A Pending JP2012046552A (ja) 2005-01-27 2011-12-06 腎細胞ガンを処置するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011266809A Pending JP2012046552A (ja) 2005-01-27 2011-12-06 腎細胞ガンを処置するための方法

Country Status (13)

Country Link
US (2) US20070014765A1 (cg-RX-API-DMAC10.html)
EP (1) EP1846020B1 (cg-RX-API-DMAC10.html)
JP (2) JP2008528621A (cg-RX-API-DMAC10.html)
KR (1) KR20070102576A (cg-RX-API-DMAC10.html)
CN (1) CN101132809A (cg-RX-API-DMAC10.html)
AU (1) AU2006207987B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0606774A2 (cg-RX-API-DMAC10.html)
CA (1) CA2595959A1 (cg-RX-API-DMAC10.html)
ES (1) ES2432141T3 (cg-RX-API-DMAC10.html)
IL (1) IL184865A (cg-RX-API-DMAC10.html)
MX (1) MX2007009012A (cg-RX-API-DMAC10.html)
RU (1) RU2404795C2 (cg-RX-API-DMAC10.html)
WO (1) WO2006081510A2 (cg-RX-API-DMAC10.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2370399A4 (en) * 2008-12-11 2013-05-22 Agency Science Tech & Res GLUCOSE-PEG CONJUGATES TO REDUCE GLUCOSE TRANSPORT INTO A CELL
US20150299255A1 (en) * 2010-11-01 2015-10-22 Susavion Biosciences, Inc. Compositions and methods for modulating innate and adaptive immune systems
WO2012088446A1 (en) * 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
EP3443979B2 (en) * 2011-03-11 2026-05-20 Assistance Publique - Hôpitaux De Paris IL-2 DOSAGE REGIMEN FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS
US9669071B2 (en) * 2011-03-11 2017-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for stimulating T lymphocytes with IL-2
CN105722860A (zh) 2013-09-24 2016-06-29 梅迪塞纳医疗股份有限公司 白介素-2融合蛋白及其应用
EP3129493B1 (en) 2014-04-09 2021-07-07 The Scripps Research Institute Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
JP6592505B2 (ja) 2014-04-24 2019-10-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
JP6640834B2 (ja) 2014-08-11 2020-02-05 デリニア, インコーポレイテッド 自己免疫疾患の処置のために調節性t細胞を選択的に活性化させる改変il−2変異体
US10350260B2 (en) * 2015-04-27 2019-07-16 Susavion Biosciences, Inc. Compositions and methods for treating cancer and persistent viral infections
EP3288576A4 (en) * 2015-04-27 2019-01-16 Susavion Biosciences, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER AND PERSISTENT VIRUS INFECTIONS
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
EP3538548A4 (en) 2016-11-08 2020-08-19 Delinia, Inc. IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
CU24483B1 (es) * 2016-11-15 2020-04-02 Ct Inmunologia Molecular Método para incrementar los niveles de secreción de la interleucina-2
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
KR102920712B1 (ko) 2017-05-24 2026-01-30 노파르티스 아게 항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
AU2018287317B2 (en) 2017-06-19 2024-06-20 Medicenna Therapeutics Inc. Uses and methods for IL-2 superagonists, agonists, and fusions thereof
TWI821192B (zh) 2017-07-11 2023-11-11 美商新索思股份有限公司 非天然核苷酸之導入及其方法
IL321812A (en) 2017-08-03 2025-08-01 Synthorx Inc Cytokine complexes for the treatment of autoimmune diseases
KR102777151B1 (ko) * 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
TW202031284A (zh) 2018-11-08 2020-09-01 美商新索思股份有限公司 介白素10結合物及其用途
MA54952A (fr) 2019-02-06 2022-05-11 Synthorx Inc Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス,インコーポレーテッド NKp30に結合する抗体分子およびその使用
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
CA3148135A1 (en) 2019-08-23 2021-03-04 Carolina E. CAFFARO Il-15 conjugates and uses thereof
WO2021050554A1 (en) 2019-09-10 2021-03-18 Synthorx, Inc. Il-2 conjugates and methods of use to treat autoimmune diseases
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
KR20220140514A (ko) 2020-01-10 2022-10-18 브라이트 피크 테라퓨틱스 아게 변형된 il-2 폴리펩타이드 및 그의 용도
MX2022008770A (es) 2020-01-14 2022-10-07 Synthekine Inc Muteinas de la il2.
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
IL301612A (en) * 2020-10-09 2023-05-01 Synthorx Inc Immuno oncology therapies with il-2 conjugates
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752585A (en) * 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4931543A (en) 1987-05-11 1990-06-05 Cetus Corporation Process for recovering microbially produced interleukin-2
US5830452A (en) * 1990-11-20 1998-11-03 Chiron Corporation Method for enhancing the anti-tumor therapeutic index of interleukin-2
CN101028523A (zh) * 1995-11-30 2007-09-05 德克萨斯州立大学董事会 诊断和治疗肿瘤的方法及组合物
ATE537842T1 (de) * 2002-07-01 2012-01-15 Wilex Ag Zusammesetzungen von cg250 und il-2 oder von cg250 und ifn-alpha zur krebsbehandlung des nierenzell karzinoms

Similar Documents

Publication Publication Date Title
RU2007132125A (ru) Способы лечения почечноклеточной карциномы
ES2380107T3 (es) Combinación de inmunogenoterapia y quimioterapia para el tratamiento del cáncer y enfermedades hiperproliferativas
JP2004524278A5 (cg-RX-API-DMAC10.html)
IL155730A (en) Compounds for the treatment of viral hepatitis C
JP2013533858A5 (cg-RX-API-DMAC10.html)
Hande et al. Randomized study of high-dose versus low-dose methotrexate in the treatment of extensive small cell lung cancer
Lissoni et al. Prognostic Factors of the Clinical Response to Subcutaneous Immunotherapy with lnterleukin-2 Alone in Patients with Metastatic Renal Cell Carcinoma
Pasricha et al. Treatment of pemphigus with cyclophosphamide
Ellerhorst et al. Phase II trial of low dose γ-interferon in metastatic renal cell carcinoma
EP1201247B1 (en) Treatment of metastatic renal cell carcinoma
JP2006514681A5 (cg-RX-API-DMAC10.html)
Johnson et al. A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas
Yamao et al. Phase I–II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer
JP2009539916A5 (cg-RX-API-DMAC10.html)
JP2007501806A5 (cg-RX-API-DMAC10.html)
Chaplin et al. Plegridy for the treatment of RRMS in adults
JP3712914B2 (ja) 腎細胞ガン処置
JP2001288110A5 (cg-RX-API-DMAC10.html)
JP2005529152A5 (cg-RX-API-DMAC10.html)
Atzpodien et al. Treatment of metastatic renal cell cancer patients with recombinant subcutaneous human interleukin-2 and interferon-α
HK1045119A1 (zh) 用於治療癌症的放射性順鉑
US20080057032A1 (en) Combination therapy (temozolomide and alpha-ifn) for advanced cancer
Suzuki et al. Dipyridamole Combined with Tumor Necrosis Factor‐α Enhances Inhibition of Proliferation in Human Tumor Cell Lines
Pavlidis et al. Phase II study of 5-fluorouracil and interferon-gamma in patients with metastatic colorectal cancer: A hellenic cooperative oncology group study
ROMINGER Hydroxyurea and radiation therapy in advanced neoplasms of the head and neck